Nathalie Garçon, PharmD, PhD is currently the Chief Executive Officer (CEO) and Chief Scientific Officer (CSO) of BIOASTER. She joined BIOASTER, the French Technology Research Institute for infectiology and microbiology as Chief Scientific Officer in July 2014. In this role, Dr. Garçon directs the scientific aspect of the institute with the objective of accelerating the access to new technologies in infectious diseases that patients can benefit from. She was promoted to CEO in April 2015.
Following the successful completion of two PhDs, one in biological pharmacy and the other in immunotoxicology and immunopharmacology, Dr. Garçon moved to the UK for one year as a postdoctoral research fellow at the Royal Free Hospital in London, undertaking research on liposomes in vaccines. She then moved to the USA, where she spent four years at Baylor College of Medicine in Houston, Texas, first as a postdoctoral research fellow, then as assistant professor, working on vaccine delivery systems and immunopotentiators.
Dr. Garçon joined SmithKline Beecham Biologicals, now GlaxoSmithKline Biologicals, in 1990, where she set up and led the vaccine adjuvant and formulation group, and held numerous senior positions. In her last role within GSK Vaccines before joining BIOASTER, Dr. Garçon held the position of Vice President, Head of Adjuvants and Technologies Innovation Centre, where she provided leadership within GSK Biologicals in the fields of new vaccines technologies, from discovery to registration and commercialization. Dr. Garçon’s expertise in vaccinology extends from research to manufacturing, in particular immunology, adjuvant and formulation technologies, analytical methods, animal experimentation, and toxicology/safety evaluation and testing.
Dr. Garçon is the 2014 laureate of the Stanley Plotkin award for vaccines and vaccine technologies. She has authored over 60 papers and book chapters, and holds more than 100 patents.
Registration is free. Please confirm your presence before February 23, 2016.